Search

Your search keyword '"Scholl, Sebastian"' showing total 59 results

Search Constraints

Start Over You searched for: Author "Scholl, Sebastian" Remove constraint Author: "Scholl, Sebastian" Publisher elsevier inc. Remove constraint Publisher: elsevier inc.
59 results on '"Scholl, Sebastian"'

Search Results

1. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia

2. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

3. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

4. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

6. Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome

7. Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

8. Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

9. Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

11. Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose

12. Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

14. Impact of KMT2A-PTD Mutational Subgroups on Outcome of AML Patients after Induction Therapy and Allogeneic Hematopoietic Cell Transplantation

15. Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

16. Secondary-Type Mutations Do Not Impact the Favorable Outcome of NPM1-Mutated Acute Myeloid Leukemia Patients - Results from a Large Cohort of Intensively Treated Patients

18. Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

19. Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents

20. Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status

21. Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

22. Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

23. Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4

24. Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit

25. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study

26. Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

27. MDS-404: Population Pharmacokinetics Modeling and Evaluation of Clinical Efficacy and Safety of Sabatolimab: Dose Selection and Dose-Response Analysis

28. MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study

29. Poster: MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study

30. Poster: MDS-404: Population Pharmacokinetics Modeling and Evaluation of Clinical Efficacy and Safety of Sabatolimab: Dose Selection and Dose-Response Analysis

31. Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial

32. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study

33. First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

34. AML-190: Anti-TIM-3 Antibody MBG453 in Combination with Hypomethylating Agents (HMAs) in Patients with High-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia: A Phase 1 Study

35. Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

36. Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

37. Incidence, Risk Factors, Treatment and Long Term Outcome of Refractory and First Relapse AML Patients in the OSHO Studies

40. EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia

41. Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia

42. Validation of a Frailty Score Predicting Survival of Elderly, Non-Fit AML Patients Receiving Hypomethylating Therapy: Results of the Decider Trial

43. Induction Therapy for AML with 90 Mg/m² Daunorubicin Results in Higher Troponin T Serum Levels in Comparison to Treatment with 60 Mg/m² Daunorubicin

44. Real World Data on Decitabine Treatment in 296 Patients with Acute Myeloid Leukemia: Outcome and Impact of TP53 Mutations

45. Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies

46. Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study

47. Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients

48. Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies

49. Prognostic Factors for Overall Survival in Relapsed Acute Myeloid Leukemia

50. Long Term Follow up of the AML97-Study for Patients with AML Older Than 60 Years: A Study of the East German Hematology and Oncology Study Group (OSHO)

Catalog

Books, media, physical & digital resources